Expediting Myasthenia Gravis (MG) Diagnostic Evaluation: A Novel, Proof-of-Concept for Undiagnosed, Symptomatic Patients That Uses Social Media Targeting and Self-Assessment
NCT ID: NCT06381284
Last Updated: 2025-03-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
215 participants
OBSERVATIONAL
2024-03-28
2025-03-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated Assessment
NCT06866483
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
NCT00727194
Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares
NCT04590716
Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod
NCT07072988
Digital Phenotyping and Lifestyle Intervention in Patients with Myasthenia Gravis
NCT05992025
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Adult participants who don't have specific diagnosed neurologic conditions will first be screened for eligibility based on the results of the IDL survey which will query participants on the presence or absence of habits/symptoms characteristic of MG. Those who qualify will complete the MG Exercise Assessment in which participants are provided video instructions to perform a series of 10 physical tests to examine if specific muscle groups undergo inducible fatigue. The results of the MG Exercise Assessment are reviewed by a neurologist to determine if participants would benefit further from an in-person neurologist evaluation for MG by a provider. Each participant is provided with a report of the neurologist's evaluation. Participants will be followed for 1 year through bimonthly communications to determine if and when they followed up with a clinician and if they received a confirmed diagnosis of myasthenia gravis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants with undiagnosed neuromuscular symptoms
Social media recruitment
Social media users exposed to a variety of paid social media advertisements as a recruitment tool for study enrollment
Self-Assessment
Eligible participants are asked to complete self-administered physical tests to assess inducible fatigue of specific muscle groups
Follow-up
Patients triaged based on their assessed risk of MG are asked to complete recommended follow-up with a clinician to determine presence of myasthenia gravis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Social media recruitment
Social media users exposed to a variety of paid social media advertisements as a recruitment tool for study enrollment
Self-Assessment
Eligible participants are asked to complete self-administered physical tests to assess inducible fatigue of specific muscle groups
Follow-up
Patients triaged based on their assessed risk of MG are asked to complete recommended follow-up with a clinician to determine presence of myasthenia gravis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 19 or older if reside in Nebraska or Alabama, Age 21 or older if reside in Mississippi, Age 18 years or older if reside in any other state
* Active email account
* Fluency in English (spoken / written), as demonstrated by the ability to read and sign the Informed Consent Form
Exclusion Criteria
* Inability or unwillingness to provide written informed consent
* Diagnosed myasthenia gravis
* Diagnosed multiple sclerosis
* Have speech impairment, eye/arm/leg weakness due to diagnosed brain cancer, or stroke
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Pharma
INDUSTRY
University of California, San Francisco
OTHER
ZS Associates
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ananda Vishnu Pandurangadu, MD
Senior Consultant
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ananda Vishnu Pandurangadu, MD
Role: PRINCIPAL_INVESTIGATOR
ZS Associates
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ZS Associates
Evanston, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Study landing page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MG-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.